Presentation is loading. Please wait.

Presentation is loading. Please wait.

Validation of select PDN drug candidates in an in vivo endotoxemia model Validation of select PDN drug candidates in an in vivo endotoxemia model Therapeutic.

Published byΒαρνάβας Αξιώτης Modified over 5 years ago

Similar presentations

Presentation on theme: "Validation of select PDN drug candidates in an in vivo endotoxemia model Validation of select PDN drug candidates in an in vivo endotoxemia model Therapeutic."— Presentation transcript:

1 Validation of select PDN drug candidates in an in vivo endotoxemia model
Validation of select PDN drug candidates in an in vivo endotoxemia model Therapeutic leads generated using PDN were directly tested for survival benefit using a murine model of endotoxemia. Select compounds were injected 24 h before and on the day of LPS administration, using routes and doses specified in the methods. C57bl/6 female mice were injected with a high‐lethality dose of Escherichia coli LPS (38–40 μg/g) followed by a subcutaneous injection of sterile saline. Significant differences in concentration between drug and vehicle‐treated pre‐ and post‐pubertal mice are labeled with ****P < 0.0001, ***P < 0.001, **P < 0.01, or *P < 0.05. Percent survival was compared using a log‐rank Mantel–Cox test. Rose B Joachim et al. Mol Syst Biol 2018;14:e7998 © as stated in the article, figure or figure legend

Download ppt "Validation of select PDN drug candidates in an in vivo endotoxemia model Validation of select PDN drug candidates in an in vivo endotoxemia model Therapeutic."

Similar presentations

Culture type shapes drug‐induced growth arrest in ovarian cancer patient cells Culture type shapes drug‐induced growth arrest in ovarian cancer patient.

Culture type shapes drug‐induced growth arrest in ovarian cancer patient cells Culture type shapes drug‐induced growth arrest in ovarian cancer patient.
Abundance of proteins matching selected subcellular locations and functions in CaCo‐2 cells. Abundance of proteins matching selected subcellular locations.

Abundance of proteins matching selected subcellular locations and functions in CaCo‐2 cells. Abundance of proteins matching selected subcellular locations.
Global comparison of MinSpan pathways with databases of human‐defined pathways The pairwise connection specificity index (CSI) was calculated for all pathway.

Global comparison of MinSpan pathways with databases of human‐defined pathways The pairwise connection specificity index (CSI) was calculated for all pathway.
Schematic diagram of the three circuits analysed in this work.

Schematic diagram of the three circuits analysed in this work.
Attema et al., Supplementary Figure 1

Attema et al., Supplementary Figure 1
Melting behavior of proteins identified in the Escherichia coli meltome and their properties Melting behavior of proteins identified in the Escherichia.

Melting behavior of proteins identified in the Escherichia coli meltome and their properties Melting behavior of proteins identified in the Escherichia.
Overview of the experimental setting.

Overview of the experimental setting.
Thermal proteome profiling in Escherichia coli

Thermal proteome profiling in Escherichia coli
Melting behavior of protein complexes

Melting behavior of protein complexes
In vivo selectivity of compound 6b.

In vivo selectivity of compound 6b.
Analysis of in silico flux changes along the exponential growth phase: (A) In silico flux changes from 24 to 36 h, from 36 to 48 h, and from 48 to 60 h.

Analysis of in silico flux changes along the exponential growth phase: (A) In silico flux changes from 24 to 36 h, from 36 to 48 h, and from 48 to 60 h.
Heatmaps of the gene mutation distributions in oncogene‐signaling blocks for six representative cancer types. Heatmaps of the gene mutation distributions.

Heatmaps of the gene mutation distributions in oncogene‐signaling blocks for six representative cancer types. Heatmaps of the gene mutation distributions.
Validation of the CCE associations by mass spectrometry.

Validation of the CCE associations by mass spectrometry.
Treatment with p38γ/p38δ inhibitor shows antifungal effects in vivo

Treatment with p38γ/p38δ inhibitor shows antifungal effects in vivo
Skin proliferation kinetics and in vivo fibroblast lineage tracing during dermal maturation (related to Fig 4)‏ Skin proliferation kinetics and in vivo.

Skin proliferation kinetics and in vivo fibroblast lineage tracing during dermal maturation (related to Fig 4)‏ Skin proliferation kinetics and in vivo.
Prediction of IGHV status based on Factor 1 in the CLL data and validation on outlier cases on independent assays Prediction of IGHV status based on Factor.

Prediction of IGHV status based on Factor 1 in the CLL data and validation on outlier cases on independent assays Prediction of IGHV status based on Factor.
Dose response of pAGA1 and pFIG1 induction

Dose response of pAGA1 and pFIG1 induction
Correlating protein to mRNA and proteins per mRNA ratios

Correlating protein to mRNA and proteins per mRNA ratios
Characterization of promoters relative to pAGA1

Characterization of promoters relative to pAGA1
Drug network derived from the core EGFR interactome and combination strategy to overcome the resistant cells. Drug network derived from the core EGFR interactome.

Drug network derived from the core EGFR interactome and combination strategy to overcome the resistant cells. Drug network derived from the core EGFR interactome.

Similar presentations

Ads by Google